20+ SynCardia Certified Centers to Present Record Number of Total Artificial Heart Abstracts at ISHLT

Topics Include Home Discharge Using the Freedom® Portable Driver and Use of the Total Artificial Heart for Adolescents, Congenital Patients and Destination Therapy

(PresseBox) ( Tucson AZ, USA, )
SynCardia Systems, Inc. (www.syncardia.com), manufacturer of the world's first and only FDA, Health Canada and CE (Europe) approved, the Total Artificial Heart, announced today that more than 20 SynCardia Certified Centers representing four countries and more than 70 authors will present a record number of abstracts discussing the SynCardia temporary Total Artificial Heart at the annual meeting of the International Society for Heart & Lung Transplantation (ISHLT) being held April 24-27 in Montreal, Canada.

“Transplant programs throughout the world are making the SynCardia Total Artificial Heart the new standard of care for end-stage biventricular heart failure,” said Michael Garippa, SynCardia Chairman/CEO/President. “SynCardia Certified Centers have amassed a wealth of knowledge and experience in using the Total Artificial Heart, and sharing this information with the international transplant community is critical to creating and sustaining good patient outcomes worldwide.”

Key ISHLT presentations on the SynCardia Total Artificial Heart, ordered by date and time, include:

Wednesday, April 24 2013

• 3:25 PM: Total Artificial Heart
Francisco A. Arabia, MD, Cedars-Sinai Heart Institute, Los Angeles CA USA
SYMPOSIUM 13: Machines vs. Medications for Biventricular Failure (2:15 PM-4:15 PM)
Room: 517CD

Thursday, April 25 2013

• 5:30 PM: Characteristics and Survival of Patients with the Total Artificial Heart Implanted for Indications Other Than Biventricular Failure
Poster Session 2: Mechanical Circulatory Support (10 AM-6:30 PM)
Room: 516

• 5:30 PM: Clinical Outcomes for INTERMACS Profile 1 Patient Implanted with the Total Artificial Heart
Poster Session 2: Mechanical Circulatory Support (10 AM-6:30 PM)
Room: 516

Friday, April 26 2013

• 5:15 PM: Worldwide Use of SynCardia Total Artificial Heart in Adolescents: A 25-Year Experience
Concurrent Session 35: PEDS 2: Mechanical Circulatory Support in Children (4-5:30 PM)
Room: 513ABC

• 5:30 PM: Home Discharge and Out-of-Hospital Follow-Up of Total Artificial Heart Patients Supported by a Portable Driver
Poster Session 3: Mechanical Circulatory Support (9 AM-6:30 PM)
Room: 516

• 6:05 PM: Long Term Results with Total Artificial Heart: Is It Prime Time for Destination Therapy?
Mini Oral Session 7: Mechanical Circulatory Support II (5:30-6:30 PM)
Room: 513DEF

Saturday, April 27 2013

• 1:03 PM: The Worldwide Use of SynCardia Total Artificial Heart in Patients with Congenital Heart Disease
Concurrent Session 41: MCS 10: Outcomes Potpourri (12:15-1:30 PM)
Room: 511

• 1:15 PM: Artificial Heart Patients Discharged Home with a Portable Pneumatic Driver -- The Pivotal US Clinical Trial Experience
Concurrent Session 44: MCS 11: Translational Science and New Devices (12:15-1:30 PM)
Room: 513ABC

In addition, on Wednesday, April 24, SynCardia will be hosting a panel discussion titled, “Moving Forward: The Freedom Experience, the Bi-Leaflet Valve TAH, and End-Organ Recovery.” Medical professionals interested in attending should contact Vivian Wessel at vwessel@syncardia.com.
Für die oben stehenden Pressemitteilungen, das angezeigte Event bzw. das Stellenangebot sowie für das angezeigte Bild- und Tonmaterial ist allein der jeweils angegebene Herausgeber (siehe Firmeninfo bei Klick auf Bild/Meldungstitel oder Firmeninfo rechte Spalte) verantwortlich. Dieser ist in der Regel auch Urheber der Pressetexte sowie der angehängten Bild-, Ton- und Informationsmaterialien.
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an service@pressebox.de.